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Plasma N-terminal pro-brain 
natriuretic peptide is a  
powerful predictor of mortality  
in hypertension
Paget et al., Hypertension 2011; 57: 702–709; doi:10.1161/
HYPERTENSIONAHA.110.163550
It has long been known that the prognostic significance of an 
elevated blood pressure is dependent on a variety of factors, chief 
among them the degree of hypertensive damage that is already 
present in the cardiovascular system. Years ago, astute clinicians 
found the observation of the retinal blood vessels particularly 
informative, and the severity of the hypertensive retinopathy was 
used to stratify the prognosis of hypertensive patients. Because left 
ventricular hypertrophy (LVH) as assessed by X-ray radiology was 
also known to be a major predictor of cardiovascular complica-
tions, assessment of left ventricular volume by ultrasonography has 
recently become the gold standard to stratify risk, despite the con-
siderable costs and required expertise of the technique. In addition, 
the substantial operator dependence of echocardiography is likely to 
generate a considerable amount of noise, so more robust and easier 
tests that could be used for risk stratification would be welcome. 
In response to volume expansion and pressure load, ventricular 
myocytes release the cardiac hormone brain natriuretic peptide 
(BNP), together with its amino-terminal fragment, N-terminal 
proBNP (NT-proBNP). Plasma levels of BNP and NT-proBNP are 
well-known prognostic markers in advanced stages of cardiac dis-
eases such as heart failure and coronary disease. In addition, plasma 
NT-proBNP was found to be closely related to LVH as assessed by 
a combination of ultrasonography and electrocardiology. To deter-
mine whether NT-proBNP might be a useful prognostic marker in 
subjects with hypertension, Paget et al. prospectively studied the 
relationship between plasma NT-proBNP and all-cause mortality 
in 684 hypertensive patients with no history or symptoms of heart 
failure. During the following 5.7 years, they observed 40 deaths 
(1.04 deaths per 100 patients per year). After adjustment for tra-
ditional cardiovascular risk factors, including ambulatory blood 
pressure and serum creatinine, the risk for all-cause mortality more 
than doubled with each increment of 1 log NT-proBNP (hazard 
ratio, 2.33; 95% confidence interval, 1.36–3.96). The risk of death 
of patients with plasma NT-proBNP ≥133 pg/ml (third tertile of the 
distribution) was 3.3 times that of patients with values <50.8 pg/ml 
(first tertile; hazard ratio, 3.30; 95% confidence interval, 0.90–12.29) 
(Figure). This predictive value was independent of, and superior to, 
that of LVH as determined electrocardiologically, and it persisted 
in patients without LVH. Thus, in this large sample of hypertensive 
patients, plasma NT-proBNP was a strong prognostic marker.
This performance, together with the ease of measurement, low cost, 
and widespread availability of the NT-proBNP test, should prompt a 
wide use of this marker for risk stratification in hypertension.
Juan Oliver
Metformin slows renal cystogenesis
Takiar et al., Proc Natl Acad Sci USA 2011; 108: 2462–2467; doi:10.1073/
pnas.1011498108
Despite much work and great advances in our understanding of 
its pathogenesis, autosomal dominant polycystic kidney disease 
(ADPKD) remains a disease for which there are no specific, effective 
therapies. As a result of slow but continuous development of cysts 
derived from renal tubular epithelial cells, the kidney architecture 
is profoundly disrupted and its function compromised. Even with 
the best efforts in blood pressure control and the like, nearly half of 
patients with ADPKD ultimately require renal replacement therapy. 
Cystic growth and expansion in ADPKD are thought to result from 
both fluid secretion into cyst lumens and abnormal proliferation of 
the cyst-lining epithelium. Because the rate of fluid secretion into 
the cyst lumen is directly proportional to the amount of the cystic 
fibrosis transmembrane conductance regulator (CFTR) chloride 
channel in the apical membranes of cyst-lining epithelial cells, pre-
clinical trials of CFTR inhibitors in cell and animal models of renal 
cystic disease are in progress. However, the cells surrounding the 
cysts also manifest increased proliferation. Since mammalian tar-
get of rapamycin (mTOR) activity is elevated in polycystic kidney 
disease models, it is thought to be involved in the hyperproliferative 
phenotype. Indeed, treatment with rapamycin has been shown to 
inhibit renal cystic expansion in several animal models of ADPKD. 
Interestingly, the CFTR chloride channel and the mTOR pathway 
are negatively regulated by the ‘energy-sensing’ molecule AMP-
activated protein kinase (AMPK); AMPK phosphorylates and 
directly inhibits CFTR and indirectly antagonizes mTOR through 
phosphorylation of tuberous sclerosis protein 2 (TSC2) and Raptor. 
Takiar et al. noted that metformin, a drug in wide clinical use, is a 
pharmacological activator of AMPK, so they explored its effect in 
renal cystic disease. They found that metformin stimulated AMPK, 
thereby inhibiting both the CFTR and the mTOR pathways. Met-
formin also induced significant arrest of cystic growth in both in 
vitro and ex vivo models of renal cystogenesis as well as significant 
decreases in the cystic index of two mouse models of ADPKD (see 
Figure as an example).
Survival curves relative to the three groups defined by tertiles of plasma 
NT-proBNP levels.
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These provocative results suggest a possible role for AMPK acti-
vation in slowing renal cystogenesis in ADPKD. Moreover, the 
large body of knowledge associated with metformin might facili-
tate analysis of the potential therapeutic use of this drug (or more 
potent, specific analogs) in ADPKD.
Juan Oliver
Estimated glomerular filtration 
rate and albuminuria as predictors 
of outcomes in patients with high 
cardiovascular risk
Clase et al., Ann Intern Med 2011; 154: 310–318
The increased cardiovascular risk among people with chronic 
kidney disease (CKD) in the general population has been well 
documented. Clase et al. pooled two trials, one testing telmisartan, 
ramipril, and a combination of these agents (ONTARGET) and 
the other comparing telmisartan and placebo (TRANSCEND), to 
evaluate the incremental risk associated with CKD in trial popu-
lations with high cardiovascular risk. Participants randomized 
in these two trials were more than 55 years of age and had docu-
mented vascular disease or diabetes with evidence of end organ 
damage. Participants with moderate or severe CKD (creatinine >3 
mg/dl) or a urinary albumin–creatinine ratio greater than 300 mg/g 
were excluded. More than 27,000 participants were included, with a 
mean estimated glomerular filtration rate (eGFR) of 73.25 ml/min 
(±19.57) and a urine albumin–creatinine ratio of 5.24 (±24.13). 
In univariate analyses, decreasing eGFRs and increasing urinary 
albumin–creatinine ratios were associated with increasing hazard 
of a cardiovascular end point. As in other analyses, the risk seemed 
to increase as eGFR fell below 60 ml/min. For urinary albumin 
excretion, the risk continued to rise with an increase in excretion 
throughout the range of available values, steeper among values less 
than 20 mg/mmol and positive, though less steep, with increasing 
values greater than this threshold. Traditional cardiovascular risk 
factors were entered into a model used to define low, intermediate, 
and high risk for the cardiovascular end points. When eGFR and 
urinary albumin–creatinine ratio were added to the model, its ability 
to predict risk was modest and did not improve significantly.
This analysis provides important indirect information on 
the role of markers of CKD in risk assessment. The study does 
not contradict prior population-based cohort studies dem-
onstrating the associations. These trials examine a small and 
very well-described proportion of the general population, but 
many hypotheses can be generated from the differences in study 
design. The association of eGFR and urinary albumin excre-
tion with morbidity and mortality in prior studies is founded 
in its ability to reflect the severity of cardiovascular disease. 
Subsequently, when the degree of cardiovascular disease is well 
described, the risk is no longer as significant. If this hypothesis 
explains these findings, it underscores the importance of meas-
uring the eGFR and urinary albumin excretion rate not only to 
evaluate kidney function but also as a noninvasive surrogate for 
cardiovascular risk in a person in whom invasive assessments 
have not been made.
Lynda Szczech
IL-9 production by regulatory  
T cells recruits mast cells that are 
essential for regulatory T cell-
induced immune suppression
Eller et al., J Immunol 2011; 186: 83–91; doi:10.4049/ jimmunol.1001183
Tipping the balance between effector and regulatory cell popu-
lations is of critical importance in the pathogenesis of various 
autoimmune disorders. CD4+CD25+Foxp3+ regulatory T cells 
(Tregs) have been demonstrated to ameliorate murine models 
of inflammation. Very recently, research demonstrated that mast 
cells can also exhibit immunomodulatory functions. To inves-
tigate possible interactions between mast cells and Tregs, Eller 
et al. used the nephrotoxic serum model of immune nephritis. 
Transfer of wild-type Tregs into wild-type recipients almost 
completely prevented development of nephrotoxic serum 
nephritis and led to an increase of mast cells in the renal drain-
ing lymph nodes. By contrast, transfer of wild-type Tregs into 
animals deficient in mast cells no longer had protective effects. 
Similarly, blocking the pleiotropic cytokine interleukin-9 (IL-9), 
involved in mast-cell activation, abrogated the protection from 
nephrotoxic serum nephritis by Tregs, as did transfer of IL-9-
deficient Tregs. In the absence of Treg-derived IL-9, mast cells 
failed to accumulate in the lymph nodes, indicating that Tregs 
generate IL-9, which attracts mast cells into renal lymph nodes, 
where they suppress the immune response of nephrotoxic serum 
and the resulting nephritis.
On the basis of these results, the authors postulate that the nephro-
protective, anti-inflammatory effects of Tregs critically depend 
on IL-9-mediated attraction of mast cells into kidney-draining lymph 
nodes. This is an intriguing new observation that generates questions 
about the mechanisms of mast cell-dependent immunosuppression in 
the regional lymph nodes and the subsequent effects on the develop-
ment of nephrotoxic serum nephritis.
Detlef Schlöndorff 
Metformin treatment reduced the cystic index in a mouse model of 
ADPKD. Representative mid-sagittal sections from the kidneys of (a) a 
wild-type mouse, (b) a mouse with deletion of renal PKD1, treated with 
metformin (Met), and (c) a mouse with deletion of renal PKD1 but given 
only vehicle.
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